Phenazopyridine

Pyridium labeling describes pain, burning, urgency/frequency and other discomfort from lower urinary mucosal irritation after infection, trauma, surgery, instrumentation or catheter passage. AZO Drug Facts describe UTI-associated pain/burning/urgency/frequency. These are label-described uses, not an FDA approval assertion: selected Rx and OTC records all show unapproved drug other.

Determine and treat the cause promptly; stop prescription therapy when symptoms are controlled. It can accompany indicated antibacterial therapy but supplies no antibacterial activity or substitute antibiotic course. Persistent symptoms require reassessment rather than ongoing masking.

Selected OTC labels limit self-use to 2 days/12 tablets; longer use requires clinician review, not authorization for a chronic course. Prescription UTI adjunct use≤2 days because benefit beyond that has not been shown. No universal longer postprocedure regimen or numerical renal reduction invented; renal insufficiency is contraindicated in selected Rx labeling.

Pyridium: previous phenazopyridine hypersensitivity and renal insufficiency. OTC kidney disease/allergy requires prior clinician review, and G6PD deficiency prohibits self-use unless physician approves. No numerical eGFR threshold or dose-adjustment strategy added to override the Rx contraindication.

Selected Pyridium/AZO labels have no boxed warning. Their SPL records are unapproved drug other; absence of a box and availability of Drug Facts do not establish FDA approval or unrestricted safety.

GI upset, headache, rash/itching and anaphylactoid reactions reported; overdose/accumulation may cause methemoglobinemia, hemolysis and kidney/liver injury. Get immediate medical/Poison Control assessment after excess dose or serious symptoms. Selected Rx mentions hospital antidote treatments, but this profile supplies no self-directed methylene-blue/ascorbate dose, home vomiting or reassurance based on urine color.

May affect color/spectrometry-based urinalysis and urine glucose/ketone tests; inform the laboratory. Selected labels do not provide a universal washout interval or alternative-method algorithm. A misleading test can delay diagnosis if exposure is not disclosed.

Selected Rx permits use alongside indicated antibacterial therapy for short UTI symptom relief, not compatibility with every drug. No comprehensive pharmacokinetic interaction table is supplied; review all urinary-pain products/ingredients to prevent duplicate phenazopyridine. Do not infer antibacterial effect or independent antibiotic choice.

Prescription renal insufficiency contraindication; no validated numerical renal/dialysis dose or safe chronic regimen provided. AZO maximum-strength insert requests liver/kidney review; accumulation can cause organ toxicity. No unsupported universal hepatic cutoff or “safe if dose halved” assertion.

AZO self-use directions ≥12; younger children need consultation and no weight-based dose is established in selected Rx. Consider age-associated renal decline in older adults rather than invent an age-only reduced dose. Keep inaccessible to children.

Pyridium human pregnancy studies inadequate; use only clearly needed after clinical review, not legacy category B safety guarantee. Human milk/metabolite data absent. AZO 99.5 mg label asks professional review if pregnant/breastfeeding and recommends pregnancy testing/consultation if confirmed. No universal reproductive-safe claim or infant dose/milk-discard interval.

Drug excreted into urine acts on urinary-tract mucosa to reduce discomfort; precise mechanism unknown. This is analgesia, not antibacterial activity, and relief does not indicate infection eradication.

Selected Pyridium says PK properties have not been determined but reports rapid renal excretion, with up to 66% of oral dose unchanged in urine. No validated half-life, therapeutic blood level, dialysis clearance or universal bioavailability is supplied; do not extrapolate other manufacturer study numbers into this label.

Review symptoms/cause, kidney/liver disease, allergies, G6PD status, age, pregnancy/lactation and duplicate products. Reassess persistent symptoms beyond 2 days or adverse effects; disclose use before laboratory tests. No routine universally required CBC or fixed renal-lab schedule invented.

Take exact strength after/with meals as directed, OTC with full glass of water. Expect orange-red urine and possible staining; do not confuse urinary analgesic with antibiotic. Do not exceed brief label course or delay definitive care. Stop for yellow skin/eyes or suspected reaction; seek emergency care for breathing difficulty/blue-gray skin or overdose. Store safely away from children.

100 mg

Deep brown/maroon round film-coated, PY over 1 one side; 100-count bottle NDC 60846-501-01.

200 mg

Same appearance, PY over 2; 100-count NDC 60846-502-01.

Regulatory category

Prescription label; both selected product records unapproved drug other, no FDA approval assertion.

Prescription

100/200 mg phenazopyridine hydrochloride; selected 100 mg count differs from OTC tablet count.

AZO original

95 mg hydrochloride tablet; selected NDC 49973-301 record, OTC Drug Facts, unapproved drug other.

AZO maximum

99.5 mg hydrochloride; NDC 49973-247 record, OTC Drug Facts/insert, unapproved drug other. Not methenamine/salicylate or cranberry products.

Scope

No unverified other strengths/routes/combination or current-stock/approval claim.

Pyridium 20–25°C with 15–30°C excursions, tight container/child-resistant closure. Selected AZO 15–30°C dry and protected from light; intact blisters/seal required. Avoid staining from tablet residue; respect expiration and exact current package.